1107015-44-0

Upstream product

• 1107015-42-8 C₁₈H₂₄F₃NO₄ 
• 1419956-93-6 4-p-tolylsulfanylcarbonyl-piperidine-1-carboxylic acid tert-butyl ester 
• 175676-65-0 2-trifluoromethoxyphenylboronic acid 
• 84358-13-4 N-[(tert-butoxy)carbonyl]piperidine-4-carboxylic acid 

Downstream Products

• 1107015-47-3 C₁₃H₁₄F₃NO₂*ClH 
• 1107178-00-6 piperidin-4-yl-(2-trifluoromethoxy-phenyl)-methanone 
• 1419957-55-3 [4-(2-trifluoromethoxy-benzoyl)-piperidin-1-yl]-acetic acid ethyl ester 
• 1419957-61-1 [4-(2-trifluoromethoxy-benzoyl)-piperidin-1-yl]-acetic acid 

Relevant academic research and scientific papers

NOVEL 2-PIPERIDIN-1-YL-ACETAMIDE COMPOUNDS FOR USE AS TANKYRASE INHIBITORS

The present invention provides for compounds of formula (I), wherein R1-R5 and L are defined herein. The present invention also provides for pharmaceutical compositions and combinations comprising a compound of formula (I) as well as for the use of such compounds as tankyrase inhibitors and in the treatment of Wnt signaling and tankyrase 1 and 2 signaling related disorders which include, but are not limited to, cancer.

Novel benzoylpiperidine-based stearoyl-CoA desaturase-1 inhibitors: Identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-ylethyl)amide and its plasma triglyceride-lowering effects in Zucker fatty rats

Starting from a known piperazine-based SCD-1 inhibitor, we obtained more potent benzoylpiperidine analogs. Optimization of the structure of the benzoylpiperidine-based SCD-1 inhibitors resulted in the identification of 6-[4-(2-methylbenzoyl)piperidin-1-yl]pyridazine-3-carboxylic acid (2-hydroxy-2-pyridin-3-yl-ethyl)amide (24) which showed strong inhibitory activity against both human and murine SCD-1. In addition, this compound exhibited good oral bioavailability and demonstrated plasma triglyceride lowering effects in Zucker fatty rats in a dose-dependent manner after a 7-day oral administration (qd).